To our knowledge, this study is the first to report that SOX9 is associated with clinical TNM stage in NSCLC, and to describe the mechanism by which SOX9 enhances Wnt/β-catenin pathway via promoting GSK3β phosphorylation at serine 9. This evidence concerns the gene SOX9 and non-small cell lung carcinoma.